Company: GIFLF
Filing Date: 2025-05-12
Form Type: 6-K
Source: 0001104659-25-047168
Chunk: 8

Company: Grifols SA
Filing Date: 2025-05-12
Form: 6-K
Chunk 8
---
 Revenue Delivers a 10.0% cc Growth LFL 1 Driven by All Business Units Note: All figures are presented on a consolidated basis (including Biotest). Percentage rates are presented at constant curre ncy (cc), excluding exchange rate fluctuations over the period. See Annex for reconciliations. 1 Like For Like (LFL) excludes the impact of IRA (EUR 28 million) and Fee - For - Service / GPO reclassification (EUR 15 million). See Annex for reconciliations. 2 Medical Diagnostics Solutions (MDS). Immunoassay Diagnostic Solutions (IDS). Blood typing Solutions (BTS). Revenues (in million EUR) 1,626 1,829 1 2 3 4 5 6 7 8 Q1’24 Biopharma Diagnostic Bio Supply & Others Q1’25 LFL Fee - for - S ervice / GPO reclassification Q1’25 Reported Inflation Reduction Act 1,786 +9.6% cc 169 +5.2% cc 12 22 15 28 +10.0% cc +7.4% cc Business Performance Financials Final Remarks Annex Biopharma I +9.6% cc LFL 1 I +6.6% cc • Strong underlying demand driven by IG franchise • As per the Plan, offset by lower albumin sales to China due to planned license renewal and phasing of Rabies Diagnostic I +5.2% cc • MDS 2 segment grew 7% cc via new business ex - US • BTS 2 grew a 4% cc, driven by expansion across core markets • IDS 2 increased by 12% cc due to joint business volume growth IRA and Fee - for - Service / GPO • IRA impact inline with forecast and guidance • Fee - for - service / GPO impact consistent with prior year incorporating this year's growth

- 7 - Q1 2025 Results Biopharma Delivers Strong Performance Led by IG Franchise 17.5% Growth LFL 1 in Q1’25 Business Performance Financials Final Remarks Annex Biopharma Immunoglobulin Albumin Alpha - 1 and Specialty P roteins • IVIG +13.5% cc LFL 1 • SCIG +98.9% cc LFL 1 • Phasing due to planned imported drug license renewal in China • Increase in Alpha - 1 • Partially offset by